TRANSACTIONS UNDER AMBU'S SHARE BUYBACK PROGRAM

23.11.2026 12:58:09 CET | Ambu A/S | Changes in company's own shares

On 5 November 2026, Ambu announced a share buyback program (company announcement no. 3 2026/27). The share buyback program is carried out in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) (as amended) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016, also referred to as the Safe Harbor Regulations.

During the program, Ambu will repurchase shares for a total amount of up to DKK 400m from 9 November 2026 until no later than 30 April 2027. The repurchased shares are bought with the purpose of reducing the share capital in accordance with Article 5(2)(a) in MAR.

The following transactions have been made under the program from 16 November 2026 to 20 November 2026:

	Number of shares	Average purchase price, DKK	Transaction value, DKK
Accumulated under the program since last announcement	**216,000**	**87.8488**	**18,975,330**
2026.11.16	38,000	91.9442	3,493,880
2026.11.17	42,000	89.6797	3,766,547
2026.11.18	40,000	90.0749	3,602,998
2026.11.19	42,000	89.2857	3,749,999
2026.11.20	45,000	88.1031	3,964,638
Accumulated under the program	**423,000**	**88.7787**	**37,553,392**

Following the transactions disclosed above, the remaining amount available under the program is DKK 362,446,608. Ambu now owns 9,064,687 treasury shares, corresponding to 3.4% of the share capital.

Contacts

- Lisa Bedell Clive, Head of Investor Relations, +44 7385 420133, licl@ambu.com
- Tine Bjørn Schmidt, Director of Global Brand & Communications, +45 2264 0697, tisc@ambu.com

About Ambu A/S

Ever since 1937, Ambu has surpassed expectations with groundbreaking solutions that improve patient care. Millions of patients, clinicians, and health systems worldwide rely on our endoscopy, anesthesia, and patient monitoring solutions for efficiency, safety, and performance. Our ownership of every stage of the product life cycle enables us to work closely with healthcare professionals, maintain a reliable product supply, and uphold full transparency. At our headquarters in Copenhagen, Denmark, and around the world in Europe, North America, and the Asia Pacific, 5,200+ Ambu team members are committed to delivering above and beyond.

Attachments

- Download announcement as PDF.pdf